Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

vaniprevir

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Hepatitis C virus (HCV) NS3/4A protease is an important and attractive target for anti-HCV drug development and discovery… Expand
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
BackgroundVaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
2014
2014
BACKGROUND & AIMS The combination of vaniprevir (a NS3/4A protease inhibitor) with peginterferon and ribavirin was shown to… Expand
Is this relevant?
2013
2013
Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in… Expand
Is this relevant?
2013
2013
BACKGROUND Vaniprevir with P/R improved SVR rates over P/R alone in treatment-experienced patients with chronic HCV-genotype 1… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Vaniprevir (MK‐7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chronic liver diseases, including… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
A highly efficient synthesis of Vaniprevir (MK-7009) has been accomplished in nine linear steps and 55% overall yield. The key… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND & AIMS The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?